Solidpharma SRL
6.0 FTEThe score of Solidpharma shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2023 → 2025: Equity +32 % Total assets +4 % Headcount (avg FTE) +7 %
Accounts of the company itself (not consolidated).
The full file covers 9 financial years; a free account shows 2. →Solidpharma's annual accounts
| 2025 | 2024 | 2023 | 2021 | 2020 | |
|---|---|---|---|---|---|
| Net result | 163,718 € | ||||
| Equity | 733,170 € | ||||
| Cash | 296,454 € | ||||
| EBITDA | 524,855 € | ||||
| Total assets | €2.28m |
Filed annual accounts
- Year ended 31 May 2025filed on 03 Jan 2026
- Year ended 31 May 2024filed on 06 Jan 2025
- Year ended 31 May 2023filed on 03 Jan 2024
- Year ended 31 Dec 2021filed on 31 Aug 2022
- Year ended 31 Dec 2020filed on 30 Aug 2021
Solidpharma's financial analysis
- Solvency32.1%sector median: 46.0%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Solidpharma
Solidpharma's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0826.168.103
- VAT number
- BE0826168103
- Peppol
- Registered · 0208:0826168103 · as of 28 Oct 2026
- Legal form
- SRL
- Incorporated
- 19 May 2010
- Registered office
- 9052 Ghent
- Size
- Micro · 6.0 FTE
- Latest accounts
- 2025 · filed on 03 Jan 2026
- Activity
- Wholesale of pharmaceutical and medical goods (NACE 46460)
Solidpharma (SRL) has been based in Ghent since 2010, active in: wholesale of pharmaceutical and medical goods. For 2025, it reports a net profit of 163,718 € and equity of 733,170 €; its revenue is not published. With 6.0 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 32.1%, below the median of its sector (46.0%).
Companies similar to Solidpharma
Companies in the same business, of comparable size and area, outside its group.
- Endoscopie Richard Wolf Belgium Wholesale of pharmaceutical and medical goods Ghent · balance sheet €3.15m
- Echomedic Wholesale of pharmaceutical and medical goods Deinze · balance sheet €1.36m
- Update Orthopaedics Associates Wholesale of pharmaceutical and medical goods Sint-Martens-Latem · balance sheet €1.70m
- BO Medicals Wholesale of pharmaceutical and medical goods Lier · balance sheet €2.55m
- Etablissementen Van Houdt Wholesale of pharmaceutical and medical goods Antwerp · balance sheet €1.90m
- Medim Wholesale of pharmaceutical and medical goods Kruisem · balance sheet €1.89m
- Dental SUD Retail sale of medical and orthopaedic goods Namur · balance sheet 34,848 €
- WM Supplies (B) Wholesale of pharmaceutical and medical goods Kuurne · balance sheet €3.17m
Frequently asked questions about Solidpharma
What is the revenue of Solidpharma?
Solidpharma files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Solidpharma?
In Belgium, the VAT number is the company number prefixed with BE: BE0826168103 for Solidpharma, if the company is VAT-registered. Its company number (CBE) is 0826.168.103.
Where is the registered office of Solidpharma?
According to the CBE register, the registered office of Solidpharma is in 9052 Ghent.
What is the equity of Solidpharma?
At the close of the 2025 financial year, the equity of Solidpharma amounts to 733,170 €, a solvency of 32.1% of total assets.
How many people work at Solidpharma?
6.0 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Solidpharma?
The register lists 2 active mandates at Solidpharma. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Solidpharma
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →